EA037447B1 - Способ лечения эозинофильных заболеваний - Google Patents
Способ лечения эозинофильных заболеваний Download PDFInfo
- Publication number
- EA037447B1 EA037447B1 EA201990529A EA201990529A EA037447B1 EA 037447 B1 EA037447 B1 EA 037447B1 EA 201990529 A EA201990529 A EA 201990529A EA 201990529 A EA201990529 A EA 201990529A EA 037447 B1 EA037447 B1 EA 037447B1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- eosinophilic
- compound
- eosinophils
- syndrome
- compounds
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
- C07D211/86—Oxygen atoms
- C07D211/88—Oxygen atoms attached in positions 2 and 6, e.g. glutarimide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Otolaryngology (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2013150861/15A RU2552929C1 (ru) | 2013-11-14 | 2013-11-14 | Фармацевтическая композиция, содержащая производные глутаримидов, и их применение для лечения эозинофильных заболеваний |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA201990529A1 EA201990529A1 (ru) | 2019-07-31 |
| EA037447B1 true EA037447B1 (ru) | 2021-03-30 |
Family
ID=53057723
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201891262A EA032955B3 (ru) | 2013-11-14 | 2014-11-12 | Применение производного глутаримида для лечения эозинофильных заболеваний |
| EA201690798A EA030961B1 (ru) | 2013-11-14 | 2014-11-12 | Применение производных глутаримидов для лечения эозинофильных заболеваний |
| EA201891261A EA032940B1 (ru) | 2013-11-14 | 2014-11-12 | Способ лечения эозинофильных заболеваний с помощью соединения производного глутаримидов |
| EA201990529A EA037447B1 (ru) | 2013-11-14 | 2014-11-12 | Способ лечения эозинофильных заболеваний |
Family Applications Before (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201891262A EA032955B3 (ru) | 2013-11-14 | 2014-11-12 | Применение производного глутаримида для лечения эозинофильных заболеваний |
| EA201690798A EA030961B1 (ru) | 2013-11-14 | 2014-11-12 | Применение производных глутаримидов для лечения эозинофильных заболеваний |
| EA201891261A EA032940B1 (ru) | 2013-11-14 | 2014-11-12 | Способ лечения эозинофильных заболеваний с помощью соединения производного глутаримидов |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US9949962B2 (enExample) |
| EP (2) | EP3466425B1 (enExample) |
| JP (4) | JP2016540749A (enExample) |
| KR (2) | KR102312294B1 (enExample) |
| CN (2) | CN105722511B (enExample) |
| AU (2) | AU2014349246C1 (enExample) |
| BR (1) | BR112016010515B1 (enExample) |
| CA (1) | CA2930231C (enExample) |
| CY (1) | CY1122500T1 (enExample) |
| DK (1) | DK3069720T3 (enExample) |
| EA (4) | EA032955B3 (enExample) |
| ES (2) | ES2759530T3 (enExample) |
| HU (1) | HUE046671T2 (enExample) |
| IL (2) | IL245429B (enExample) |
| LT (1) | LT3069720T (enExample) |
| MX (2) | MX386887B (enExample) |
| PL (2) | PL3466425T3 (enExample) |
| PT (1) | PT3069720T (enExample) |
| RU (1) | RU2552929C1 (enExample) |
| SG (1) | SG10201900504XA (enExample) |
| SI (1) | SI3069720T1 (enExample) |
| UA (1) | UA118687C2 (enExample) |
| WO (1) | WO2015072893A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7608693B2 (en) | 2006-10-02 | 2009-10-27 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-4 receptor |
| NZ630178A (en) | 2012-09-07 | 2017-06-30 | Regeneron Pharma | Methods for treating atopic dermatitis by administering an il-4r antagonist |
| CN110229140B (zh) * | 2013-04-12 | 2022-06-10 | 制药有限责任公司 | 戊二酰亚胺衍生物、其用途、基于所述衍生物的药物组合物及戊二酰亚胺衍生物的制备方法 |
| TWI682781B (zh) | 2013-07-11 | 2020-01-21 | 美商再生元醫藥公司 | 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法 |
| KR20160120735A (ko) | 2014-02-28 | 2016-10-18 | 리제너론 파아마슈티컬스, 인크. | Ｉｌ-4ｒ 길항제의 투여에 의한 피부 감염의 치료 방법 |
| US11771743B2 (en) | 2016-09-01 | 2023-10-03 | Regeneron Pharmaceuticals, Inc. | Methods for preventing or treating allergy by administering an IL-4R antagonist |
| CN106539792B (zh) * | 2016-11-07 | 2017-08-25 | 王晓旭 | 一种治疗高血脂症的药物 |
| EA201992341A8 (ru) * | 2017-09-07 | 2020-08-11 | Общество С Ограниченной Ответственностью "Фарминтерпрайсез" | Применение производного глутаримида для лечения заболеваний, связанных с аберрантной активностью цитокинов |
| RU2712281C1 (ru) | 2018-11-23 | 2020-01-28 | Общество С Ограниченной Ответственностью "Хемиммьюн Терапьютикс" | Применение производного глутаримида для преодоления резистентности к стероидам и терапии заболеваний, ассоциированных с аберрантным сигналингом интерферона гамма |
| KR20210143246A (ko) | 2019-03-21 | 2021-11-26 | 리제너론 파아마슈티컬스, 인크. | 알레르기 치료용 il-4/il-13 경로 억제제 및 형질 세포 절제의 병용 |
| EP4010373A1 (en) | 2019-08-05 | 2022-06-15 | Regeneron Pharmaceuticals, Inc. | Methods for treating atopic dermatitis by administering an il-4r antagonist |
| KR20220042217A (ko) | 2019-08-05 | 2022-04-04 | 리제너론 파아마슈티컬스, 인크. | Il-4r 길항제를 투여함에 의해 알레르기를 치료하고 알레르겐-특이적 면역치료요법을 증진시키기 위한 방법 |
| KR20230058590A (ko) * | 2020-04-07 | 2023-05-03 | 호프세드 바이오케어 에이에스에이 | 연어과 오일 조성물을 사용하는 호흡기 치료 |
| CN115803026A (zh) * | 2020-06-26 | 2023-03-14 | 瓦伦塔有限责任公司 | 戊二酰亚胺衍生物用于治疗与异常白介素-6活性相关的疾病的用途 |
| WO2023113650A1 (ru) * | 2021-12-15 | 2023-06-22 | Владимир Евгеньевич НЕБОЛЬСИН | Фармацевтическая композиция 1-[2-(1-метилимидазол-4-ил)-этил]пергидроазин-2,6-дион для терапии заболеваний верхних дыхательных путей |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994024133A1 (en) * | 1993-04-09 | 1994-10-27 | Cell Therapeutics, Inc. | Ring-substituted cell signaling inhibitors |
| WO2007000246A1 (en) * | 2005-06-28 | 2007-01-04 | Sanofi-Aventis | Heteroaryl-substituted amides comprising a saturated linker group, and their use as pharmaceuticals |
| RU2378284C2 (ru) * | 2008-02-13 | 2010-01-10 | Общество С Ограниченной Ответственностью "Фарминтерпрайсез" | Способы получения n-ацильных производных аминокислот (варианты) |
| RU2406727C2 (ru) * | 2008-02-13 | 2010-12-20 | Общество С Ограниченной Ответственностью "Фарминтерпрайсез" | Фармацевтическая композиция, содержащая n-ацильные производные аминокислот, и их применение в качестве противоаллергических, антианафилактических и противовоспалительных средств |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH02196767A (ja) * | 1988-10-11 | 1990-08-03 | Kyowa Hakko Kogyo Co Ltd | ヒドロキサム酸誘導体 |
| CA2097607A1 (en) * | 1990-12-24 | 1992-06-24 | Marcel Hibert | Use of certain glutarimide derivatives in the treatment of depression and mania |
| AUPO005496A0 (en) | 1996-05-24 | 1996-06-13 | Bresagen Limited | An interleukin-5 antagonist |
| RU2141483C1 (ru) | 1997-07-04 | 1999-11-20 | Небольсин Владимир Евгеньевич | Производные пептидов или их фармацевтически приемлемые соли, способ их получения, применение и фармацевтическая композиция |
| NZ532516A (en) | 2001-11-07 | 2008-05-30 | Cytos Biotechnology Ag | Antigen arrays presenting IL-5, IL-13 or eotaxin for treatment of allergic eosinophilic diseases |
| WO2007007054A1 (en) | 2005-07-08 | 2007-01-18 | Cancer Research Technology Limited | Phthalamides, succinimides and related compounds and their use as pharmaceuticals |
| DK2068927T3 (da) | 2007-05-14 | 2016-01-18 | Medimmune Llc | Fremgangsmåder til reducering af eosinofilniveauer |
| CN110229140B (zh) * | 2013-04-12 | 2022-06-10 | 制药有限责任公司 | 戊二酰亚胺衍生物、其用途、基于所述衍生物的药物组合物及戊二酰亚胺衍生物的制备方法 |
-
2013
- 2013-11-14 RU RU2013150861/15A patent/RU2552929C1/ru active
-
2014
- 2014-11-12 SG SG10201900504XA patent/SG10201900504XA/en unknown
- 2014-11-12 PL PL18206980T patent/PL3466425T3/pl unknown
- 2014-11-12 DK DK14861410T patent/DK3069720T3/da active
- 2014-11-12 BR BR112016010515-0A patent/BR112016010515B1/pt not_active IP Right Cessation
- 2014-11-12 US US15/036,603 patent/US9949962B2/en active Active
- 2014-11-12 KR KR1020167013675A patent/KR102312294B1/ko not_active Expired - Fee Related
- 2014-11-12 CA CA2930231A patent/CA2930231C/en active Active
- 2014-11-12 JP JP2016530898A patent/JP2016540749A/ja not_active Ceased
- 2014-11-12 HU HUE14861410A patent/HUE046671T2/hu unknown
- 2014-11-12 CN CN201480062492.5A patent/CN105722511B/zh not_active Expired - Fee Related
- 2014-11-12 ES ES14861410T patent/ES2759530T3/es active Active
- 2014-11-12 EA EA201891262A patent/EA032955B3/ru not_active IP Right Cessation
- 2014-11-12 ES ES18206980T patent/ES2836887T3/es active Active
- 2014-11-12 WO PCT/RU2014/000855 patent/WO2015072893A1/ru not_active Ceased
- 2014-11-12 CN CN201910373584.XA patent/CN110200968A/zh active Pending
- 2014-11-12 MX MX2019006881A patent/MX386887B/es unknown
- 2014-11-12 EP EP18206980.7A patent/EP3466425B1/en active Active
- 2014-11-12 AU AU2014349246A patent/AU2014349246C1/en not_active Ceased
- 2014-11-12 EP EP14861410.0A patent/EP3069720B1/en active Active
- 2014-11-12 PL PL14861410T patent/PL3069720T3/pl unknown
- 2014-11-12 EA EA201690798A patent/EA030961B1/ru not_active IP Right Cessation
- 2014-11-12 LT LTEP14861410.0T patent/LT3069720T/lt unknown
- 2014-11-12 PT PT148614100T patent/PT3069720T/pt unknown
- 2014-11-12 KR KR1020207013125A patent/KR102312013B1/ko not_active Expired - Fee Related
- 2014-11-12 MX MX2016006330A patent/MX365781B/es active IP Right Grant
- 2014-11-12 SI SI201431407T patent/SI3069720T1/sl unknown
- 2014-11-12 EA EA201891261A patent/EA032940B1/ru not_active IP Right Cessation
- 2014-11-12 EA EA201990529A patent/EA037447B1/ru unknown
- 2014-12-11 UA UAA201606370A patent/UA118687C2/uk unknown
-
2016
- 2016-05-01 IL IL245429A patent/IL245429B/en active IP Right Grant
-
2017
- 2017-12-18 US US15/844,703 patent/US10220029B2/en active Active
-
2018
- 2018-10-30 JP JP2018203599A patent/JP6589251B2/ja active Active
- 2018-11-15 AU AU2018264084A patent/AU2018264084C1/en not_active Ceased
-
2019
- 2019-08-21 JP JP2019151253A patent/JP6758677B2/ja not_active Expired - Fee Related
- 2019-08-21 JP JP2019151258A patent/JP2020002152A/ja not_active Ceased
- 2019-11-19 CY CY20191101215T patent/CY1122500T1/el unknown
- 2019-12-11 IL IL271352A patent/IL271352B/en active IP Right Grant
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994024133A1 (en) * | 1993-04-09 | 1994-10-27 | Cell Therapeutics, Inc. | Ring-substituted cell signaling inhibitors |
| WO2007000246A1 (en) * | 2005-06-28 | 2007-01-04 | Sanofi-Aventis | Heteroaryl-substituted amides comprising a saturated linker group, and their use as pharmaceuticals |
| RU2378284C2 (ru) * | 2008-02-13 | 2010-01-10 | Общество С Ограниченной Ответственностью "Фарминтерпрайсез" | Способы получения n-ацильных производных аминокислот (варианты) |
| RU2406727C2 (ru) * | 2008-02-13 | 2010-12-20 | Общество С Ограниченной Ответственностью "Фарминтерпрайсез" | Фармацевтическая композиция, содержащая n-ацильные производные аминокислот, и их применение в качестве противоаллергических, антианафилактических и противовоспалительных средств |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6758677B2 (ja) | グルタルイミド誘導体を含む医薬組成物、及び好酸球性疾患を処置するためのその適用 | |
| WO2017202276A1 (zh) | 苯醚类衍生物、及其制法和药物组合物与用途 | |
| Zhang et al. | Design, synthesis, and bioevaluation of novel NLRP3 inhibitor with IBD immunotherapy from the virtual screen | |
| JP2024170448A (ja) | メイソインジゴの多形体およびメイソインジゴの改変された製剤 | |
| US20210205348A1 (en) | Methods for the Treatment of Bladder Cancer | |
| HK40007097A (en) | Use of glutarimide derivatives in the treatment of eosinophilic diseases | |
| HK40007097B (en) | Use of glutarimide derivatives in the treatment of eosinophilic diseases | |
| HK1224930A1 (en) | Pharmaceutical composition containing glutarimide derivatives, and application thereof for treating eosinophilic diseases | |
| CN113637019A (zh) | 一种选择性jak1抑制剂化合物及其制备方法和用途 | |
| HK1224930B (zh) | 包含戊二酰亚胺衍生物的药物组合物及其用於治疗嗜酸细胞性疾病的用途 |